Applying generic vendor checklists to drug development creates operational risk. Traditional biologics and cell or gene therapies demand vastly different risk profiles, analytical assays, and cold-chain logistics. This framework outlines the core CDMO selection criteria for biologics and advanced therapies, covering nine areas to ask and verify. Built for biopharma leaders evaluating partners across monoclonal antibodies, proteins, cell therapies, and gene therapies, it helps prevent tech transfer failures before they start. Start with modality fit. Everything else cascades from that.
1. Align the CDMO Manufacturing Platform with Your Specific Modality
The largest operational delays in tech transfer stem from platform mismatch rather than pricing or facility size. A top-tier CHO biologics partner is often the wrong fit for viral vectors or autologous cell processing.
Request concrete evidence over marketing claims to verify capability:
| Manufacturing Modality | CDMO Capability Evidence to Request |
|---|---|
| Biologics | Request CHO platform maturity metrics, confirmation that upstream and downstream equipment fits the process, and evidence of scale-up experience at the target production volume. |
| Cell and Gene Therapies (CGT) | Verify experience with the specific vector type, such as AAV or lentivirus, along with closed-system automation capabilities and multi-product containment protocols. |
Quick Decision Rule: If your asset requires scale-out or patient-specific manufacturing, treat logistics and analytics as first-order criteria rather than secondary add-ons.
For a closer look at where manufacturing strategy is headed for these modalities, see our analysis of CMC considerations for cell and gene therapies.
2. Evaluate Analytical Method Development and Potency Assay Depth
Analytical methods and potency assays often form the critical path for IND-enabling studies and long-term comparability. For cell and gene therapies and complex biologics, simply running standard release tests is insufficient. Your CDMO must possess internal expertise to develop, optimize, and validate custom assays rather than just execute routine testing.
What to Verify |
|
|---|---|
| Assay Menu and Validation | Confirm capabilities for cell-based potency, flow cytometry, ddPCR, and NGS, backed by clear method lifecycle ownership and a phase-appropriate validation strategy. |
| Development Track Record | Review anonymized transfer timelines, example protocols, and dedicated analytical staffing models. |
Red Flags to Scan For
- A CDMO that says it outsources potency testing entirely.
- Unclear assay ownership or no plan for phase-appropriate validation.
3. Evaluate QMS Maturity and Operational Quality Culture
A weak Quality Management System (QMS) rarely reveals itself during initial vendor discussions. Instead, underlying quality gaps surface late through batch disposition delays, repeat deviations, and regulatory inspection findings during clinical development.
Translate quality claims into verifiable execution during diligence:
| QMS Risk Area | Diligence Evidence to Review |
|---|---|
| Regulatory Footprint | Review recent FDA or EMA inspection history, including Form 483 response thoroughness and internal remediation governance. |
| Quality Culture Signals | Audit deviation throughput, CAPA aging trends, batch record review cycle times, and verified training effectiveness across technical teams. |
Practical Audit Move: Ask scenario-based questions during facility audits. For example: walk us through a critical deviation from the past year, and describe the systemic process changes that followed.
These lapses are not hypothetical. See our breakdown of how quality gaps impact drug development timelines for real-world examples across active programs.
4. Build a Concrete Tech Transfer Execution Plan and Comparability Protocol
Tech transfer failures rarely stem from facility limitations. They occur when teams rely on presentation slides rather than actionable execution plans, underestimating analytical readiness, CPP and CQA controls, and scale logic.
What to Verify |
|
|---|---|
| Written Transfer Plan | Deliverables, clear acceptance criteria, operator training, batch documentation expectations, and change-control interfaces. |
| Scale Logic | Process scale-up for biologics versus scale-out for advanced therapies, including bridging batches, pilot runs, and formal comparability protocols. |
What to Request: A phase-appropriate timeline highlighting critical path dependencies, particularly potency assay readiness. Defining these inputs early prevents hidden failure modes from surfacing after signature, when schedule recovery is most expensive.
For a concrete example of this working in practice, review our cell therapy technology transfer case study.
5. Validate Capacity Realism and Commercial Governance
Capacity constraints cause missed clinical milestones far more often than per-batch pricing variations. Evaluate true operational bandwidth rather than relying on facility marketing schedules.
What to Verify |
|
|---|---|
| Capacity Realism | Confirm suite availability, raw material lead times, campaign planning cycles, and analytical testing queue times. |
| Commercial Mechanics | Audit slot reservation fees, take-or-pay clauses, cancellation or change fees, and contractual definitions of expedited runs. |
Tier-1 vs. Boutique Tradeoffs
Global Tier-1 CDMOs offer extensive installed capacity and multi-site redundancy, but smaller programs risk deprioritization behind commercial assets. Boutique CDMOs provide flexible scheduling and dedicated senior attention, though with limited surge capacity. Choose based on whether operational agility or scale protects your critical path.
Not sure whether your program needs Tier-1 scale or boutique agility? Our team can help you weigh the tradeoffs against your timeline.
6. Treat Autologous Supply Chain and Logistics as a Core CMC Requirement
For autologous cell therapies, supply chain logistics are an extension of the drug product itself. Failures in Chain of Identity (COI) or Chain of Custody (COC) are direct patient-safety events, not routine commercial losses.
What to Verify |
|
|---|---|
| Identity and Labeling Controls | Validated electronic tracking, standardized accessioning, stringent labeling controls, and formal deviation handling for identity events. |
| Cold Chain Infrastructure | Reliable cryostorage, continuous real-time temperature monitoring, integrated courier services, and clear responsibilities across the sponsor, CDMO, and clinic. |
Red Flags
- Manual tracking or paper-based processes.
- Ambiguous handoffs between couriers and manufacturing sites.
- Lack of dry-run rehearsals for temperature excursions or mislabeling scenarios.
7. Audit Raw Material Sourcing, Lead Times, and Change Control Protocols
Unannounced material substitutions or extended lead times can delay clinical batches and trigger costly comparability studies. For cell and gene therapies (CGT) and high-risk single-source inputs like specialized media or custom single-use assemblies, disciplined material governance protects your regulatory timeline.
What to Verify |
|
|---|---|
| Material Responsibility Matrix | Define sponsor-supplied versus CDMO-supplied items, vendor qualification processes, and dual-sourcing strategies for critical components. |
| Change Control Expectations | Verify how supplier substitutions are evaluated against Critical Quality Attributes (CQAs) and regulatory filing strategies before the change goes into effect. |
Commercial Reality Check: Ask candidates for historical examples of material shortages, their mitigation tactics, and the procedural updates made to prevent recurrence.
8. Define Batch Failure Mechanics, RCA Expectations, and Liability Caps
When a batch fails, contract ambiguity determines whether you recover time and capital or absorb the loss. Aligning the Master Services Agreement (MSA) with the Quality Agreement establishes explicit risk allocation before technical issues arise.
What to Verify |
|
|---|---|
| Root Cause Analysis (RCA) Mechanics | Establish explicit investigation timelines, governance protocols, and fault buckets distinguishing CDMO execution failure, sponsor-supplied material issues, and force majeure. |
| Remedies and Exposure Caps | Define reperformance obligations, raw material reimbursement, liability carve-outs for gross negligence or willful misconduct, and aligned commercial insurance requirements. |
Practical Diligence Prompt: Ask prospective partners how many batch failures occurred at this site for your modality last year, and what operational changes followed the root cause investigation.
9. Establish Operational Governance, Joint KPIs, and Continuity Protocols
Most CDMO failures appear to be technical execution errors, but the root cause is usually weak governance. Unclear ownership, slow decisions, and unmanaged scope changes derail timelines before a batch ever fails on the manufacturing floor.
To turn vendor promises into an operating system, verify these elements during diligence:
| Governance Failure Area | What to Confirm During Diligence | Operational Risk Addressed |
|---|---|---|
| Named Roles and Continuity | Confirm dedicated project managers, MSAT leads, and QA heads, along with staff turnover plans that mitigate attrition risk. | Unclear ownership, slow escalation, and delayed decisions during deviations or schedule conflicts. |
| Joint KPIs | Track shared metrics, including on-time release, deviation closure time, modality-specific first-time-right execution, and change-control cycle time. | Unmanaged scope changes, timeline drift, and weak accountability before batch execution fails. |
Simplify governance, technical diligence, and decision documentation with Syner-G’s CDMO selection management services.
Frequently Asked Questions
How is selecting a biologics CDMO different from selecting a cell or gene therapy CDMO?
Biologics manufacturing focuses on platform scale-up, throughput, and standardized analytical methods. Cell and gene therapy (CGT) manufacturing, by contrast, hinges on custom potency and identity assays, strict viral containment, and complex scale-out logistics. Aligning manufacturing platforms and evaluating analytical depth serve as the primary gating criteria before you look at broader operations. See sections 1 and 2 above for the detailed breakdown.
Should we choose a Tier-1 global CDMO or a boutique specialist?
Tier-1 CDMOs provide extensive capacity, standardized platforms, and proven inspection histories, but emerging programs risk deprioritization behind commercial assets. Boutique specialists offer operational flexibility and deep modality expertise, provided you verify their QMS maturity. A phased strategy often works best: use boutique agility for early clinical development, then transition or dual-source with a Tier-1 partner for commercial scale.
Who pays for a failed batch, and how do we avoid surprises?
Financial responsibility depends on Root Cause Analysis (RCA) and explicit fault allocation. If execution failure rests with the CDMO, contracts typically cover batch reperformance, but raw material reimbursement requires explicit negotiated terms. Insist on defined RCA investigation timelines, remedies, and clear liability caps in the Master Services Agreement. See section 8 above for batch failure mechanics.
What evidence verifies genuine experience with viral vectors and cell therapies?
Request modality-specific first-time-right yield metrics, anonymized case studies, assay validation protocols, and recent regulatory audit outcomes. During facility walk-throughs, inspect physical viral segregation protocols, electronic Chain of Identity and Chain of Custody workflows, and analytical release testing throughput rather than relying on promotional presentations.
Do you offer tools or structured processes to manage CDMO selection?
Yes. Syner-G provides structured evaluation frameworks to simplify vendor selection across biologics and cell and gene therapy programs. Read our guide on tools to facilitate the CDMO selection process for actionable templates, or contact our team to learn how CDMO selection management drives technical due diligence and partner alignment.
Choosing between CDMO partners for biologics and advanced therapies comes down to modality fit first, then quality culture, capacity realism, and governance discipline. Each of the nine criteria above protects a different failure point in your program, and skipping any one of them raises real technical and regulatory risk.
